Compare KGS & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | CRNX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2023 | 2018 |
| Metric | KGS | CRNX |
|---|---|---|
| Price | $56.69 | $35.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $52.50 | ★ $74.78 |
| AVG Volume (30 Days) | ★ 1.3M | 885.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,308,100,000.00 | $1,039,000.00 |
| Revenue This Year | $10.92 | $730.30 |
| Revenue Next Year | $7.31 | $179.48 |
| P/E Ratio | $62.53 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $29.25 | $24.10 |
| 52 Week High | $58.50 | $57.99 |
| Indicator | KGS | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.75 | 28.30 |
| Support Level | $33.49 | $35.43 |
| Resistance Level | $58.50 | $37.23 |
| Average True Range (ATR) | 1.96 | 1.60 |
| MACD | -0.45 | 0.01 |
| Stochastic Oscillator | 68.88 | 8.48 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.